Septerna, Inc.

Septerna, Inc.

NNASDAQ:SEPN
41.67
USD
-0.93
(-2.18%)
-1.30EPS
1.86BMarket Cap
Apr 01Next Earn
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
0.11
1.04
2.12
Basic EPS, GAAP
-1.42
0.21
-7.26
-1.1
-1.3
Free Cash Flow per Basic Share
-1.26
-2.13
-7.03
2.48
-1.71
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
-1.05
-0.91
9.46
8.52
9.03
Tangible Book Value per Share
-1.05
-0.91
9.46
8.52
9.03
Basic Weighted Avg Shares
19
19
10
44
45
Sales/Revenue/Turnover
- -
- -
1
46
96
Operating Margin (%)
- -
-30,165.56
-7,518.42
-175.83
-76.23
Depreciation Expense
1
1
1
2
2
Net Income, GAAP
-28
4
-72
-49
-59
Effective Tax Rate (%)
- -
14.19
- -
- -
- -
Profit Margin (%)
- -
2,768.21
-6,678.88
-106.37
-61.29
Working Capital
26
106
344
324
402
LT Debt
- -
13
24
21
19
Total Equity
-44
-38
420
382
428
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-12.06
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-12.19
-14.45

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
2
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
21
20
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
45
46
47
Market Capitalization
1,079
1,529
1,855

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
368
396
507
Cash, Cash Equivalents & STI
347
372
479
Accounts Receivable, Net
11
12
19
Inventories
- -
- -
- -
Total Current Liabilities
78
79
105
Payables & Accruals
13
14
21
ST Debt
2
2
3
Deferred Revenue
60
60
76

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-9.08%
Free Cash Flow
- -
- -
-257.63%
Net Income, GAAP
- -
- -
-31.92%
Sales/Revenue/Turnover
- -
- -
4,174.51%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
21
24
46
2026
27
27
19
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.34
-0.39
-0.49
-0.64
-7.26
2025
-0.49
-0.56
0.18
-0.24
-1.1
2026
-0.19
-0.29
-0.57
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Jeffrey T. Finer
Full Time Employees
130
Sector
Health technology
Industry
Biotechnology
Address
250 East Grand Avenue South San Francisco CA United States 94080
IPO Date
Oct 25, 2024
Business
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company that discovers and develops oral small molecule therapeutics targeting G protein-coupled receptors (GPCRs) using its proprietary, industrial-scale Native Complex Platform. The company advances a wholly owned pipeline focused initially on endocrinology, immunology and inflammation, and metabolic diseases, including SEP-479, an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) for hypoparathyroidism; SEP-631, an oral small molecule negative allosteric modulator (NAM) of MAS-related G protein-coupled receptor X2 (MRGPRX2) for chronic spontaneous urticaria and other mast cell-driven diseases; and a TSHR program featuring an oral small molecule NAM of the thyroid-stimulating hormone receptor (TSHR) for Graves' disease and thyroid eye disease. Additional research areas span neurology, women's health, cardiovascular disease, and respiratory disease; partnered metabolic programs target obesity, type 2 diabetes, and other cardiometabolic conditions via small molecule agonists of GLP-1R, GIPR, and GCGR receptors. Septerna serves patients with significant unmet needs across these therapeutic segments through novel mechanistic approaches, including agonists, antagonists, and allosteric modulators enabled by biomarker-driven strategies. Founded in 2019 and headquartered in South San Francisco, California, the company--formerly known as GPCR NewCo, Inc., with a name change in June 2021--went public on Nasdaq in October 2024. In a major strategic development, Septerna entered a global collaboration with Novo Nordisk in May 2025 to discover, develop, and commercialize multiple oral small molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases targeting specified GPCR targets including GLP-1, GIP, and glucagon receptors; the agreement provides over $200 million in upfront and near-term payments, potential milestones exceeding $2.2 billion, tiered royalties on global net sales, and an option for Septerna to participate in worldwide profit-sharing for one program, with Novo Nordisk funding all research and development expenses post-IND-enabling activities for partnered programs. Recent pipeline progress includes dosing of the first participants in the Phase 1 clinical trial of SEP-631 in 2025 and advancement of SEP-479 and TSHR programs toward clinical stages, alongside reporting third quarter 2025 financial results that highlight a cash position extended beyond early 2028. Septerna operates primarily from the United States with no disclosed subsidiaries or parent entities.

Company News

  • Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript

  • Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE?

  • Septerna: The SEP-479 Readout Could Unlock Further Upside

  • Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

  • Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

  • Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

  • Septerna to Participate in Upcoming Investor Conferences

  • Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of Stock

  • CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey

  • Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

  • Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)

  • VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPN

  • Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Septerna to Participate in Upcoming Investor Conferences

  • Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

  • Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

  • Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

  • Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

  • Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

  • Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting